Sight Sciences (SGHT) Competitors $4.23 +0.11 (+2.67%) Closing price 04:00 PM EasternExtended Trading$4.23 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SGHT vs. TNDM, KMTS, EMBC, SIBN, BBNX, AXGN, BVS, SMLR, ZIMV, and AVNSShould you be buying Sight Sciences stock or one of its competitors? The main competitors of Sight Sciences include Tandem Diabetes Care (TNDM), Kestra Medical Technologies (KMTS), Embecta (EMBC), SiBone (SIBN), Beta Bionics (BBNX), AxoGen (AXGN), Bioventus (BVS), Semler Scientific (SMLR), ZimVie (ZIMV), and AVANOS MEDICAL (AVNS). These companies are all part of the "medical equipment" industry. Sight Sciences vs. Its Competitors Tandem Diabetes Care Kestra Medical Technologies Embecta SiBone Beta Bionics AxoGen Bioventus Semler Scientific ZimVie AVANOS MEDICAL Sight Sciences (NASDAQ:SGHT) and Tandem Diabetes Care (NASDAQ:TNDM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment. Which has more risk & volatility, SGHT or TNDM? Sight Sciences has a beta of 2.44, suggesting that its stock price is 144% more volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Does the media favor SGHT or TNDM? In the previous week, Tandem Diabetes Care had 2 more articles in the media than Sight Sciences. MarketBeat recorded 7 mentions for Tandem Diabetes Care and 5 mentions for Sight Sciences. Tandem Diabetes Care's average media sentiment score of 1.71 beat Sight Sciences' score of 0.34 indicating that Tandem Diabetes Care is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sight Sciences 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tandem Diabetes Care 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is SGHT or TNDM more profitable? Tandem Diabetes Care has a net margin of -20.51% compared to Sight Sciences' net margin of -64.23%. Sight Sciences' return on equity of -59.38% beat Tandem Diabetes Care's return on equity.Company Net Margins Return on Equity Return on Assets Sight Sciences-64.23% -59.38% -36.43% Tandem Diabetes Care -20.51%-65.40%-13.87% Do insiders & institutionals hold more shares of SGHT or TNDM? 55.5% of Sight Sciences shares are owned by institutional investors. 30.9% of Sight Sciences shares are owned by company insiders. Comparatively, 1.9% of Tandem Diabetes Care shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation & earnings, SGHT or TNDM? Sight Sciences has higher earnings, but lower revenue than Tandem Diabetes Care. Sight Sciences is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSight Sciences$79.87M2.77-$51.51M-$0.96-4.41Tandem Diabetes Care$940.20M0.86-$96.03M-$3.09-3.86 Do analysts rate SGHT or TNDM? Sight Sciences presently has a consensus target price of $4.42, suggesting a potential upside of 4.41%. Tandem Diabetes Care has a consensus target price of $22.47, suggesting a potential upside of 88.32%. Given Tandem Diabetes Care's higher probable upside, analysts plainly believe Tandem Diabetes Care is more favorable than Sight Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sight Sciences 0 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.43Tandem Diabetes Care 0 Sell rating(s) 11 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.27 SummarySight Sciences and Tandem Diabetes Care tied by winning 8 of the 16 factors compared between the two stocks. Get Sight Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGHT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SGHT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SGHT vs. The Competition Export to ExcelMetricSight SciencesMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$215.75M$6.88B$5.76B$9.58BDividend YieldN/A1.31%4.41%4.09%P/E Ratio-4.4127.4531.1026.05Price / Sales2.7775.30436.12105.98Price / CashN/A21.3437.7358.48Price / Book3.166.889.536.61Net Income-$51.51M$176.42M$3.26B$265.56M7 Day Performance0.71%0.58%2.11%1.98%1 Month Performance18.49%-0.45%5.12%1.33%1 Year Performance-33.07%13.07%31.25%21.15% Sight Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SGHTSight Sciences1.4911 of 5 stars$4.23+2.7%$4.42+4.4%-35.3%$215.75M$79.87M-4.41210News CoverageAnalyst ForecastTNDMTandem Diabetes Care4.6029 of 5 stars$10.11-10.0%$22.67+124.2%-74.1%$758.80M$940.20M-3.272,650Analyst ForecastKMTSKestra Medical TechnologiesN/A$14.65+0.9%$27.33+86.6%N/A$745.58M$59.81M0.00300Positive NewsEMBCEmbecta4.8376 of 5 stars$12.73+3.7%$19.00+49.3%+3.0%$717.67M$1.12B8.902,100Positive NewsHigh Trading VolumeSIBNSiBone4.1865 of 5 stars$15.40-1.8%$23.67+53.7%+3.6%$676.45M$167.18M-27.50350News CoverageInsider TradeBBNXBeta Bionics2.6633 of 5 stars$14.30-3.0%$22.56+57.7%N/A$640.75M$65.12M0.00294News CoveragePositive NewsInsider TradeAXGNAxoGen3.0378 of 5 stars$14.01+0.8%$26.00+85.6%+22.6%$639.58M$187.34M-140.09450Short Interest ↑BVSBioventusN/A$6.93+0.1%$13.75+98.4%-22.4%$569.26M$564.14M-11.361,200SMLRSemler Scientific3.6261 of 5 stars$35.28-2.4%$81.75+131.7%+2.5%$534.89M$56.29M14.52120ZIMVZimVie0.7222 of 5 stars$18.83+0.1%$17.75-5.7%+9.6%$530.46M$449.75M-26.901,770Positive NewsShort Interest ↑AVNSAVANOS MEDICAL3.3111 of 5 stars$10.52-2.8%N/A-52.0%$502.08M$687.80M-1.042,227Short Interest ↑ Related Companies and Tools Related Companies TNDM Alternatives KMTS Alternatives EMBC Alternatives SIBN Alternatives BBNX Alternatives AXGN Alternatives BVS Alternatives SMLR Alternatives ZIMV Alternatives AVNS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SGHT) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sight Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sight Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access